Amgen Inc. (AMGN) UBS Global Healthcare Conference (Transcript)

Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ET

Company Participants

Peter Griffith – CFO
Narimon Honarpour – SVP, Global Development
Justin Claeys – VP, IR

Conference Call Participants

Trung Huynh – UBS

Trung Huynh

Okay, great. I think that’s quarter past. Good morning, everyone. My name is Trung Huynh, I’m the large cap pharma, biopharma analyst here at UBS. It’s my great pleasure to welcome team Amgen. We’ve got Peter Griffith here, CFO of the company. We’re also joined by Narimon Honarpour. Hopefully, I’ve pronounced that correctly, Senior Vice President of Global Development; and Justin, who everyone here knows and loves from IR. So team, thank you very much for making that short trip over. I do have one point of admin. So anyone — if anyone in the audience has any questions, you would have an app, please go into that app and ask the question. Hopefully, it will come on this iPad and I can read it for your behalf. But with that said, perhaps, Peter, why don’t you start with some opening remarks, and we can go from there.

Peter Griffith

Sure. And thank you very much. We are so glad to be here today. And innovation continues to move at speed and scale at Amgen. And I’ll — Narimon and I will address in a moment, the research note that was published yesterday. But before that, let’s talk about Amgen broadly. Four therapeutic areas, all doing very, very well. Maybe starting in that with our rare disease portfolio, up to $1.2 billion in revenue in the third quarter up about 21% year-over-year, led by four products in rare disease that are early in their life cycle doing really well; TEPEZZA, KRYSTEXXA, TAVNEOS and UPLIZNA. And UPLIZNA is doing really well in the pipeline, too. I’m sure we’ll visit today about UPLIZNA and IgG4 related disease and our data there and also our data that